HUA MEDICINE (SHANGHAI) LTD. Financials Hua Medicine (Shanghai) Ltd. OTC Markets
Equities
HUMDF
KYG4644K1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2028 USD | -54.93% |
|
-.--% | -.--% |
| 03-28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 7,688 | 4,214 | 4,628 | 2,956 | 3,194 | 1,752 |
| Enterprise Value (EV) 1 | 6,245 | 3,198 | 3,676 | 2,352 | 2,801 | 459.4 |
| P/E ratio | -0.72 x | -9.92 x | -11.8 x | -9.08 x | -15.7 x | -8.28 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 842 x | 189 x | 534 x | 455 x | 181 x | 22.9 x |
| EV / Revenue | 684 x | 144 x | 424 x | 362 x | 159 x | 6 x |
| EV / EBITDA | -17.4 x | -7.22 x | -10.6 x | -7.76 x | -11 x | -1.43 x |
| EV / FCF | -50.6 x | -18.9 x | -21.5 x | -13.1 x | -5.34 x | 1.84 x |
| FCF Yield | -1.98% | -5.3% | -4.66% | -7.63% | -18.7% | 54.3% |
| Price to Book | 4.87 x | 4 x | 6.35 x | 6.61 x | 11.5 x | 17.4 x |
| Nbr of stocks (in thousands) | 1,054,894 | 941,156 | 949,630 | 957,120 | 966,841 | 978,722 |
| Reference price 2 | 7.288 | 4.477 | 4.873 | 3.088 | 3.303 | 1.791 |
| Announcement Date | 29/04/19 | 22/04/20 | 22/04/21 | 19/04/22 | 26/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 9.129 | 22.26 | 8.664 | 6.49 | 17.6 | 76.61 |
| EBITDA 1 | -358.8 | -442.9 | -347.4 | -303.2 | -254.8 | -322.2 |
| EBIT 1 | -360.3 | -446.2 | -352.4 | -315.2 | -267.1 | -338.1 |
| Operating Margin | -3,947.14% | -2,004.9% | -4,067.2% | -4,856.39% | -1,517.8% | -441.28% |
| Earnings before Tax (EBT) 1 | -3,604 | -425.3 | -393.1 | -325.7 | -203.5 | -211.2 |
| Net income 1 | -3,603 | -425.3 | -393.1 | -325.7 | -203.5 | -211.2 |
| Net margin | -39,464.63% | -1,910.72% | -4,537.56% | -5,019.01% | -1,156.36% | -275.73% |
| EPS 2 | -10.07 | -0.4514 | -0.4136 | -0.3402 | -0.2105 | -0.2162 |
| Free Cash Flow 1 | -123.4 | -169.5 | -171.3 | -179.4 | -524.5 | 249.6 |
| FCF margin | -1,351.45% | -761.36% | -1,977.69% | -2,764.1% | -2,980.47% | 325.85% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/04/19 | 22/04/20 | 22/04/21 | 19/04/22 | 26/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 17.6 | 70.33 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -163.1 | -160.2 | -140.8 | -126.3 | -133.9 |
| Operating Margin | - | - | - | - | - | - | -717.63% | -190.37% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2000 | -0.1800 | -0.2300 | -0.1700 | -0.1700 | -0.1100 | -0.1000 | -0.0900 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 16/03/20 | 17/08/20 | 19/03/21 | 19/08/21 | 16/03/22 | 25/08/22 | 29/03/23 | 24/08/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,443 | 1,016 | 951 | 604 | 393 | 1,293 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -123 | -169 | -171 | -179 | -525 | 250 |
| ROE (net income / shareholders' equity) | -1,564% | -34.5% | -43.8% | -55.1% | -55.8% | -111% |
| ROA (Net income/ Total Assets) | -25.9% | -20.3% | -18% | -18.7% | -16.5% | -14.8% |
| Assets 1 | 13,886 | 2,093 | 2,189 | 1,738 | 1,234 | 1,423 |
| Book Value Per Share 2 | 1.500 | 1.120 | 0.7700 | 0.4700 | 0.2900 | 0.1000 |
| Cash Flow per Share 2 | 1.540 | 1.170 | 1.080 | 0.7000 | 0.5100 | 1.490 |
| Capex 1 | 4.23 | 9.02 | 24.4 | 20.2 | 4.56 | 9.74 |
| Capex / Sales | 46.34% | 40.53% | 281.26% | 311.19% | 25.9% | 12.72% |
| Announcement Date | 29/04/19 | 22/04/20 | 22/04/21 | 19/04/22 | 26/04/23 | 25/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.49
Average target price
-
| 1st Jan change | Capi. | |
|---|---|---|
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B | |
| +77.64% | 8.87B |
- Stock Market
- Equities
- 2552 Stock
- HUMDF Stock
- Financials Hua Medicine (Shanghai) Ltd.
